Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gabor Gyülveszi"'
Autor:
Paulina Kulig, Stephanie Musiol, Sandra Nicole Freiberger, Bettina Schreiner, Gabor Gyülveszi, Giancarlo Russo, Stanislav Pantelyushin, Kenji Kishihara, Francesca Alessandrini, Thomas Kündig, Federica Sallusto, Günther F.L. Hofbauer, Stefan Haak, Burkhard Becher
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
IL-12 and IL-23 share the common p40 subunit yet have distinct immunological functions with IL-12 typically contributing to Th1 responses and IL-23 to Th17 responses. Here the authors show that current p40 based therapies for psoriasis are counterpro
Externí odkaz:
https://doaj.org/article/65cfea74d59d466a9e896738ae39f149
Autor:
Christian Taube, Christine Tertilt, Gabor Gyülveszi, Nina Dehzad, Katharina Kreymborg, Kristin Schneeweiss, Erich Michel, Sebastian Reuter, Jean-Christophe Renauld, Danielle Arnold-Schild, Hansjörg Schild, Roland Buhl, Burkhard Becher
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21799 (2011)
Interleukin (IL)-22 is an effector cytokine, which acts primarily on epithelial cells in the skin, gut, liver and lung. Both pro- and anti-inflammatory properties have been reported for IL-22 depending on the tissue and disease model. In a murine mod
Externí odkaz:
https://doaj.org/article/85a04ec9fb114ed1b21edbb64297cbef
Autor:
Paulina Kulig, Stefan Haak, Stanislav Pantelyushin, Gabor Gyülveszi, Federica Sallusto, Burkhard Becher
Publikováno v:
The Journal of Immunology. 190:131.17-131.17
Cytokines are key mediators of immune responses and IL-23 is a critical player in psoriasis pathogenesis. New effective monoclonal antibody directed against common subunit p40 of both IL-12 and IL-23 is currently used in clinics to treat plaque type
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/dd617d4c8dec489abc04451dc8b00545